Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11555054B2 · kind B2 · utility
0Cited by
18References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2020 |
| Grant date | Jan 17, 2023 |
| Priority date | — |
| Expiry date | Aug 26, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of Formula I, and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.